In a meta-analysis of contemporary hypertension trials, ACE inhibitors vs. all comparators reduced all-cause mortality by 10% (P < 0.05), whereas ARBs in a parallel meta-analysis were associated with no reduction in mortality. The gene discussed is ACE; the disease is hypertensive disorder.